METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH DECITABINE AND CEDAZURIDINE
Provided herein are methods of treating myelodysplastic syndromes (MDS) in a subject in need thereof. Also provided herein are methods of treating lower-risk MDS and chronic myelomonocytic leukemia (CMML) in a subject in need thereof. Also provided herein are methods of treating lower-risk MDS and chronic myelomonocytic leukemia (CMML) in a subject having a TP53 mutation in need thereof. Such methods include administering to the subject an effective amount of cedazuridine and an effective amount of decitabine, thereby treating the myelodysplastic syndrome. Such methods may increase the subject's survival (e.g., overall median survival) to about 130% to about 400% relative to survival obtained by treatment with a hypomethylating agent alone.
1 . A method of treating myelodysplastic syndromes (MDS) in a subject in need thereof, comprising
administering to the subject an effective amount of cedazuridine and an effective amount of decitabine, thereby treating the MDS,
wherein administering the effective amount of cedazuridine and the effective amount of decitabine increases survival and/or leukemia-free survival of the subject to about 130% to about 400% relative to survival or leukemia-free survival, respectively, obtained by treatment with a hypomethylating agent alone; and/or provides the subject with a survival and/or leukemia-free survival of at least about 28, 30, 32, or 34 months.
2 . The method of claim 1 , wherein the subject is at least 75 years old.
3 . (canceled)
4 . The method of claim 1 , wherein the effective amount of cedazuridine and the effective amount of decitabine are administered together in a combination solid oral dosage form.
5 . The method of claim 1 , wherein the effective amount of cedazuridine and the effective amount of decitabine are administered on days 1-5 of a 28-day cycle.
6 . (canceled)
7 . The method of claim 1 , wherein the effective amount of cedazuridine and the effective amount of the decitabine are present in a solid oral dosage form that comprises 100 mg cedazuridine, 35 mg decitabine, and at least one pharmaceutically acceptable excipient.
8 - 15 . (canceled)
16 . The method of claim 1
wherein administering the effective amount of cedazuridine and the effective amount of decitabine increases survival and/or leukemia-free survival of the subject to about 200% to about 400% relative to survival or leukemia-free survival, respectively, obtained by providing best supportive care alone.
17 - 18 . (canceled)
19 . A method of treating lower-risk MDS in a subject in need thereof, comprising
administering to the subject an effective amount of cedazuridine and an effective amount of decitabine, thereby treating the lower-risk MDS,
wherein administering the effective amount of cedazuridine and the effective amount of decitabine increases survival and/or leukemia-free survival of the subject to about 130% to about 400% relative to survival or leukemia-free survival, respectively, obtained by treatment with a hypomethylating agent alone; and/or provides the subject with a survival and/or leukemia-free survival of at least about 28, 30, 32, or 34 months.
20 - 22 . (canceled)
23 . The method of claim 19 , wherein the effective amount of cedazuridine and the effective amount of decitabine are administered on days 1-5 of a 28-day cycle.
24 . (canceled)
25 . The method of claim 19 , wherein the effective amount of cedazuridine and the effective amount of the decitabine are present in a solid oral dosage form that comprises 100 mg cedazuridine, 35 mg decitabine, and at least one pharmaceutically acceptable excipient.
26 - 33 . (canceled)
34 . The method of claim 19
wherein administering the effective amount of cedazuridine and the effective amount of decitabine increases survival and/or leukemia-free survival of the subject to about 200% to about 400% relative to survival or leukemia-free survival, respectively, obtained by providing best supportive care alone.
35 - 36 . (canceled)
37 . A method of treating chronic myelomonocytic leukemia (CMML) in a subject in need thereof, comprising
administering to the subject an effective amount of cedazuridine and an effective amount of decitabine, thereby treating the CMML,
wherein administering the effective amount of cedazuridine and the effective amount of decitabine increases survival and/or leukemia-free survival of the subject to about 130% to about 400% relative to the survival or leukemia-free survival, respectively, obtained by treatment with a hypomethylating agent alone; and/or provides the subject with a survival and/or leukemia-free survival of at least about 28, 30, 32, or 34 months.
38 - 40 . (canceled)
41 . The method of claim 37 , wherein the effective amount of cedazuridine and the effective amount of decitabine are administered on days 1-5 of a 28-day cycle.
42 . (canceled)
43 . The method of claim 37 , wherein the effective amount of cedazuridine and the effective amount of the decitabine are present in a solid oral dosage form that comprises 100 mg cedazuridine, 35 mg decitabine, and at least one pharmaceutically acceptable excipient.
44 - 51 . (canceled)
52 . The method of claim 37
wherein administering the effective amount of cedazuridine and the effective amount of decitabine increases survival and/or leukemia-free survival of the subject to about 200% to about 375% relative to survival or leukemia-free survival, respectively, obtained by providing best supportive care alone.
53 - 54 . (canceled)
55 . A method of treating MDS or CMML in a subject having a TP53 mutation in need thereof, comprising
administering to the subject an effective amount of cedazuridine and an effective amount of decitabine, thereby treating the MDS or CMML,
wherein administering the effective amount of cedazuridine and the effective amount of decitabine increases survival and/or leukemia-free survival of the subject to about 130% to about 400% relative to survival or leukemia-free survival, respectively, obtained by treatment with a hypomethylating agent alone; and/or provides the subject with a survival and/or leukemia-free survival of at least about 20, 22, 24, 26, 28, 30, 32, 34, or 36 months for a subject with a mono-allelic TP53 mutation or at least about 10, 12, 14, 16, 18, or 20 months for a subject with a bi-allelic TP53 mutation.
56 - 58 . (canceled)
59 . The method of claim 55 , wherein the effective amount of cedazuridine and the effective amount of decitabine are administered on days 1-5 of a 28-day cycle.
60 . (canceled)
61 . The method of claim 55 , wherein the effective amount of cedazuridine and the effective amount of the decitabine are present in a solid oral dosage form that comprises 100 mg cedazuridine, 35 mg decitabine, and at least one pharmaceutically acceptable excipient.
62 - 69 . (canceled)
70 . The method of claim 55
wherein administering the effective amount of cedazuridine and the effective amount of decitabine increases survival and/or leukemia-free survival of the subject to about 200% to about 400% relative to survival or leukemia-free survival, respectively, obtained by providing best supportive care alone.
71 - 87 . (canceled)
88 . A kit comprising one or more doses (e.g., 1, 2, 3, 4, or 5) of an effective amount of cedazuridine (e.g., 100 mg) and one or more doses (e.g., 1, 2, 3, 4, or 5) of an effective amount of decitabine (e.g., 35 mg) for the use in the method of claim 1 .
89 . A combination comprising one or more doses (e.g., 1, 2, 3, 4, or 5) of an effective amount of cedazuridine (e.g., 100 mg) and one or more doses (e.g., 1, 2, 3, 4, or 5) of an effective amount of decitabine (e.g., 35 mg) for the use in the method of claim 1 .